OBJECTIVE: To know the real life clinical performance of the prescription of two drugs for the treatment of vaginal discharge syndrome (Fluconazole-Secnidazole and Terconazole-Clindamycin) and to compare the clinical outcomes. MATERIALS AND METHODS: An analytical cohort study was conducted. We included women older than 18 years with a diagnosis of vaginal discharge syndrome who were candidates to be treated with Fluconazole-Secnidazole or Terconazole-Clindamycin with 8 days (ampersand-flag-changeplusmn;3) of follow-up, in 12 cities of Colombia. This project was approved by a research with human being’s ethics committee. RESULTS: 176 patients were included, 153 (86.9percent-flag-change) completed the follow-up, their age ranged between 18 and 67 years. 134 (76.1percent-flag-change) started treatment with Fluconazole-Secnidazole and 42 (23.8percent-flag-change) Terconazole-Clindamycin. Symptoms improvement was compared (Enrollment vs. Control), finding for Fluconazole-Secnidazole and Terconazole-Clindamycin: discharge (p=0.0000), pruritus (p=0.002), irritation (p=0.0000), bad smell (p=0.001) and dyspareunia (p=0.4). CONCLUSIONS: The prescription of the combination Fluconazole-Secnidazole was more frequent. The adherence to treatment was 86percent-flag-change. The proportion of improvement in symptoms ranged between 15percent-flag-change and 40percent-flag-change, however, for the case of vaginal dis-charge it was greater than 70percent-flag-change (Fluconazole-Secnidazole: 115/121 and Terconazole-Clindamycin: 29/41).
